Aldeyra Therapeutics: Reproxalap's March 2026 FDA Decision Is The Defining Catalyst [Seeking Alpha]
Aldeyra Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist [Yahoo! Finance]
Aldeyra Therapeutics, Inc. (ALDX) Discusses PDUFA Target Action Date Extension for Reproxalap in Dry Eye Disease Transcript [Seeking Alpha]
Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease [Yahoo! Finance]
Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease